Composition per tablet: Paracetamol 500 mg + Caffeine Anhydrous 30 mg + Phenylephrine Hydrochloride 10 mg.
Dosage form: Tablet; coating and appearance to be confirmed from the approved label.
Category: Cold & Flu / Analgesic formulations
Therapeutic category: Analgesic, antipyretic, caffeine adjuvant, decongestant ingredient.
SKU: paracetamol-caffeine-phenylephrine-hcl-tablets
Categories: Tablets Manufacturer, Uncategorized
Paracetamol, Caffeine & Phenylephrine Hydrochloride Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufacturing company: Healthy Life Pharma Pvt. Ltd. (facility certification and manufacturing arrangements to be verified).
Export partner: Healthy Inc (export status and market authorisations to be verified).
This three-ingredient formulation combines paracetamol for fever and pain, caffeine as a stimulant and analgesic adjuvant, and oral phenylephrine hydrochloride, a sympathomimetic traditionally included in cold medicines as a decongestant. The supplied formula is 500 mg / 30 mg / 10 mg per tablet.
Regulatory note: Evidence does not support oral phenylephrine at standard OTC doses as an effective nasal decongestant. Its regulatory status and permitted claims vary by country. Avoid describing this combination as proven to unblock the nose or as guaranteed “non-drowsy” relief.
| Product Name | Paracetamol, Caffeine & Phenylephrine Hydrochloride Tablets |
|---|---|
| Composition | Paracetamol 500 mg + Caffeine Anhydrous 30 mg + Phenylephrine HCl 10 mg |
| Dosage Form | Tablet; film-coating status subject to actual approved specification |
| Therapeutic Class | Analgesic / Antipyretic / Stimulant adjuvant / Sympathomimetic ingredient |
| Pharmacopoeial Standard | Confirm applicable IP/BP/USP monographs and finished-product specification |
| Shelf Life | As supported by product-specific stability data |
| Packaging | Blister/strip configuration subject to approved pack specification |
Development should address blend uniformity for the lower-dose caffeine and phenylephrine components, API compatibility, moisture exposure, and reproducible disintegration and dissolution. Granulation method, excipients, coating and packaging must be selected from validated development and stability data rather than assumed.
Product-specific quality controls should include identification and assay of all three active ingredients, content uniformity, dissolution/disintegration as applicable, related substances including relevant paracetamol impurities, microbial quality where required, and stability in the proposed market pack. Acceptance limits must follow the approved specification; fixed universal assay or release percentages should not be claimed without evidence.
Any cold-and-flu indication or marketing statement must be supported by the approved label in the destination market. This product does not treat the underlying viral infection.
Registration may require a country-specific formulation assessment, quality dossier, stability data, artwork and approved indications. CTD/ACTD, COA, FSC and COPP availability should be confirmed with the manufacturer. Oral phenylephrine regulatory developments require particular review before export or OTC promotion.
Q: What is the stated composition?
A: Paracetamol 500 mg, Caffeine Anhydrous 30 mg and Phenylephrine Hydrochloride 10 mg per tablet.
Q: Is it guaranteed to be non-drowsy?
A: No. The absence of a sedating antihistamine does not guarantee alertness; individual reactions vary, and caffeine can cause restlessness.
Q: Does oral phenylephrine reliably relieve a blocked nose?
A: Clinical evidence has raised substantial concerns about its effectiveness at standard oral OTC doses. Claims must follow current local regulatory requirements.
Q: Can it be combined with another cold medicine?
A: Check all ingredients first. Taking multiple paracetamol-containing medicines can cause an accidental overdose.
Use only according to the locally approved product label or a qualified clinician's instructions. Do not apply an assumed tablet frequency or maximum daily tablet count without checking the approved strength, age restrictions, other medicines and patient factors.
Store as stated on the approved product label, in the original pack and protected from inappropriate heat and moisture. Exact temperature limits and expiry must be supported by stability data.
For informational B2B product presentation only. Claims, regulatory status, indications, dosage, certification and manufacturing details require verification before publication or distribution.